Search Results - "MU SUN"

DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load by Jung, Hyunchul, Kim, Hong Sook, Kim, Jeong Yeon, Sun, Jong-Mu, Ahn, Jin Seok, Ahn, Myung-Ju, Park, Keunchil, Esteller, Manel, Lee, Se-Hoon, Choi, Jung Kyoon

“…Mitotic cell division increases tumour mutation burden and copy number load, predictive markers of the clinical benefit of immunotherapy. Cell division…”
Get full text

Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma by Kim, Nayoung, Kim, Hong Kwan, Lee, Kyungjong, Hong, Yourae, Cho, Jong Ho, Choi, Jung Won, Lee, Jung-Il, Suh, Yeon-Lim, Ku, Bo Mi, Eum, Hye Hyeon, Choi, Soyean, Choi, Yoon-La, Joung, Je-Gun, Park, Woong-Yang, Jung, Hyun Ae, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-Ju, Lee, Hae-Ock

“…Advanced metastatic cancer poses utmost clinical challenges and may present molecular and cellular features distinct from an early-stage cancer. Herein, we…”
Get full text

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study by Sun, Jong-Mu, Shen, Lin, Shah, Manish A, Enzinger, Peter, Adenis, Antoine, Doi, Toshihiko, Kojima, Takashi, Metges, Jean-Philippe, Li, Zhigang, Kim, Sung-Bae, Cho, Byoung Chul, Mansoor, Wasat, Li, Shau-Hsuan, Sunpaweravong, Patrapim, Maqueda, Maria Alsina, Goekkurt, Eray, Hara, Hiroki, Antunes, Luis, Fountzilas, Christos, Tsuji, Akihito, Oliden, Victor Castro, Liu, Qi, Shah, Sukrut, Bhagia, Pooja, Kato, Ken

“…First-line therapy for advanced oesophageal cancer is currently limited to fluoropyrimidine plus platinum-based chemotherapy. We aimed to evaluate the…”
Get full text

Covid-19 vaccine effectiveness during Omicron BA.2 pandemic in Shanghai: A cross-sectional study based on EMR by Xu, Site, Sun, Mu

“…Large-scale vaccination against the spread and mutation of COVID-19 is being implemented in many countries. We aimed to assess the effectiveness of certain…”
Get full text

The interpretable machine learning model associated with metal mixtures to identify hypertension via EMR mining method by Xu, Site, Sun, Mu

“…There are limited data available regarding the connection between hypertension and heavy metal exposure. The authors intend to establish an interpretable…”
Get full text

MDSC subtypes and CD39 expression on CD8+ T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC by Koh, Jiae, Kim, Youjin, Lee, Kyoung Young, Hur, Joon Young, Kim, Mi Soon, Kim, Boram, Cho, Hee Jin, Lee, Yeong Chan, Bae, Yeon Hee, Ku, Bo Mi, Sun, Jong‐Mu, Lee, Se‐Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung‐Ju

“…The major suppressive immune cells in tumor sites are myeloid derived suppressor cells (MDSCs), tumor‐associated macrophages (TAMs), and Treg cells, and the…”
Get full text

On the optimal redundancy allocation for multi-state series–parallel systems under epistemic uncertainty by Sun, Mu-Xia, Li, Yan-Fu, Zio, Enrico

“…•We study the redundancy allocation problem for multi-state series–parallel systems under epistemic uncertainty.•The objective is to simultaneously maximize…”
Get full text

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study by Shen, Lin, Kato, Ken, Kim, Sung-Bae, Ajani, Jaffer A, Zhao, Kuaile, He, Zhiyong, Yu, Xinmin, Shu, Yongqian, Luo, Qi, Wang, Jufeng, Chen, Zhendong, Niu, Zuoxing, Zhang, Longzhen, Yi, Tienan, Sun, Jong-Mu, Chen, Jianhua, Yu, Guohua, Lin, Chen-Yuan, Hara, Hiroki, Bi, Qing, Satoh, Taroh, Pazo-Cid, Roberto, Arkenau, Hendrick-Tobias, Borg, Christophe, Lordick, Florian, Li, Liyun, Ding, Ningning, Tao, Aiyang, Shi, Jingwen, Van Cutsem, Eric

“…Patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) have poor prognosis. For these patients, treatment options are limited after…”
Get full text

Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab by Eun, Yeonghee, Kim, In Young, Sun, Jong-Mu, Lee, Jeeyun, Cha, Hoon-Suk, Koh, Eun-Mi, Kim, Hyungjin, Lee, Jaejoon

“…We investigated risk factors for immune-related adverse events (irAEs) in patients treated with anti-programmed cell death protein1 antibody pembrolizumab. A…”
Get full text

Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity by Kim, Kwoneel, Kim, Hong Sook, Kim, Jeong Yeon, Jung, Hyunchul, Sun, Jong-Mu, Ahn, Jin Seok, Ahn, Myung-Ju, Park, Keunchil, Lee, Se-Hoon, Choi, Jung Kyoon

“…Neoantigen burden is regarded as a fundamental determinant of response to immunotherapy. However, its predictive value remains in question because some tumours…”
Get full text

Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer by Jung, Hyun Ae, Noh, Jae Myoung, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Ahn, Myung-Ju, Pyo, Hongryull, Ahn, Yong Chan, Park, Keunchil

“…•Real world data showed 55.3 % of patients did not meet the criteria of the PACIFIC study.•The incidence of grade 3 radiation pneumonitis was 18.2 % in…”
Get full text

Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma by Park, Sehhoon, Oh, Dongryul, Choi, Yoon‐La, Chi, Sang Ah, Kim, Kyunga, Ahn, Myung‐Ju, Sun, Jong‐Mu

“…Background The current standard treatment for patients with inoperable, locally advanced esophageal squamous cell carcinoma (ESCC) is definitive concurrent…”
Get full text

High concordance of actionable genomic alterations identified between circulating tumor DNA–based and tissue‐based next‐generation sequencing testing in advanced non–small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program by Park, Sehhoon, Olsen, Steve, Ku, Bo Mi, Lee, Min‐Sang, Jung, Hyun‐Ae, Sun, Jong‐Mu, Lee, Se‐Hoon, Ahn, Jin Seok, Park, Keunchil, Choi, Yoon‐La, Ahn, Myung‐Ju

“…Background Because of the growing number of actionable biomarkers in non–small cell lung cancer (NSCLC), sufficient tissue availability for testing is becoming…”
Get full text

Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer by Park, Sehhoon, Ock, Chan-Young, Kim, Hyojin, Pereira, Sergio, Park, Seonwook, Ma, Minuk, Choi, Sangjoon, Kim, Seokhwi, Shin, Seunghwan, Aum, Brian Jaehong, Paeng, Kyunghyun, Yoo, Donggeun, Cha, Hongui, Park, Sunyoung, Suh, Koung Jin, Jung, Hyun Ae, Kim, Se Hyun, Kim, Yu Jung, Sun, Jong-Mu, Chung, Jin-Haeng, Ahn, Jin Seok, Ahn, Myung-Ju, Lee, Jong Seok, Park, Keunchil, Song, Sang Yong, Bang, Yung-Jue, Choi, Yoon-La, Mok, Tony S, Lee, Se-Hoon

“…Biomarkers on the basis of tumor-infiltrating lymphocytes (TIL) are potentially valuable in predicting the effectiveness of immune checkpoint inhibitors (ICI)…”
Get full text

KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer by Kato, Ken, Shah, Manish A, Enzinger, Peter, Bennouna, Jaafar, Shen, Lin, Adenis, Antoine, Sun, Jong-Mu, Cho, Byoung Chul, Özgüro lu, Mustafa, Kojima, Takashi, Kostorov, Vladimir, Hierro, Cinta, Zhu, Ying, McLean, Lee Anne, Shah, Sukrut, Doi, Toshihiko

“…Treatment options for patients with advanced esophageal or esophagogastric junction (EGJ) cancer are limited. Current guidelines for first-line treatment of…”
Get full text

Genomic landscape of acquired resistance to third‐generation EGFR tyrosine kinase inhibitors in EGFR T790M‐mutant non–small cell lung cancer by Lee, Jiyun, Kim, Hong Sook, Lee, Boram, Kim, Hee Kyung, Sun, Jong‐Mu, Ahn, Jin Seok, Ahn, Myung‐Ju, Park, Keunchil, Lee, Se‐Hoon

“…Background EGFR tyrosine kinase inhibitors (TKIs) have shifted the treatment paradigm in advanced EGFR‐mutant non–small cell lung cancer (NSCLC). However,…”
Get full text

A critical review of key odorants in green tea: Identification and biochemical formation pathway by Yin, Peng, Kong, Ya-Shuai, Liu, Pan-Pan, Wang, Jing-Jing, Zhu, Yao, Wang, Guang-Ming, Sun, Mu-Fang, Chen, Yi, Guo, Gui-Yi, Liu, Zhong-Hua

“…Green tea, which is non-fermented, has the longest production history in China and the rest of the world. Due to the unique processing techniques, green tea…”
Get full text

Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC by Kim, Youjin, Lee, Boram, Shim, Joon Ho, Lee, Se-Hoon, Park, Woong-Yang, Choi, Yoon-La, Sun, Jong-Mu, Ahn, Jin Seok, Ahn, Myung-Ju, Park, Keunchil

“…EGFR-mutant NSCLC displays diverse outcomes to tyrosine kinase inhibitor (TKI) treatment. Because co-occurring genomic alterations might describe different…”
Get more information

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer by Ku, Bo Mi, Bae, Yeon Hee, Lee, Kyoung Young, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-Ju

“…Summary Entrectinib is a pan-tyrosine-kinase inhibitor that targets oncogenic rearrangements in NTRK , ROS1 and ALK . The combined results of two clinical…”
Get full text

Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune‐related hepatitis in non–small cell lung cancer patients with chronic hepatitis B by Hong, Joohyun, Lee, Jiyun, Park, Sehhoon, Jung, Hyun‐Ae, Sun, Jong‐Mu, Lee, Se‐Hoon, Ahn, Jin Seok, Sinn, Dong Hyun, Ahn, Myung‐Ju

“…Background The safety of immune‐checkpoint inhibitors (ICIs) has not been thoroughly investigated in non–small cell lung cancer (NSCLC) patients with chronic…”
Get full text